Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0QU8H
|
||||
| Former ID |
DPR000002
|
||||
| Drug Name |
(S)-amisulpride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Discontinued in Phase 4 | [1] | ||
| Company |
Sanofi-Aventis
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H43NO18
|
||||
| Canonical SMILES |
CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O<br />)O)NC4C=C(C(C(C4O)O)O)CO
|
||||
| InChI |
1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-/m1/s1
|
||||
| InChIKey |
XUFXOAAUWZOOIT-SXARVLRPSA-N
|
||||
| CAS Number |
CAS 71675-92-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
825251, 834618, 7885684, 7888168, 10299511, 12012879, 14964694, 26702476, 36887324, 46391424, 46393315, 49689717, 49853891, 50752736, 57404612, 81062582, 87544180, 92729723, 99437067, 103023822, 103585278, 104038074, 104631735, 123121432, 124757133, 125083567, 125163937, 134338965, 134339490, 135692087, 136368136, 144115532, 144205150, 162023511, 162037530, 170464784, 172386359, 175269637, 175611917, 176484930, 177748581, 178103397, 179116541, 210279189, 210281512, 223984695, 226406984, 241376066, 250133961, 252156703
|
||||
| SuperDrug ATC ID |
N05AL05
|
||||
| SuperDrug CAS ID |
cas=071675859
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [1] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.